

LINCOLN PHARMACEUTICALS LIMITED

Regd. Office: "LINCOLN HOUSE", B/H. SATYAM COMPLEX, SCIENCE CITY ROAD, SOLA, AHMEDABAD-380 060.
Tel. No. :- 079-67778000, Fax. No.-079-67778062. email id: info@lincolnpharma.com., CIN-L24230GJ1995PLC024288

UN-AUDITED FINANCIAL RESULTS (PROVISIONAL) FOR THE QUARTER ENDED ON 30.06.2014

(Rs. in Lacs)

PART - I		CONSOLIDATED				STANDALONE			
PARTICULARS		QUARTER ENDED		YEAR ENDED	QUARTER ENDED		YEAR ENDED		
		30.06.2014	31.03.2014	30.06.2013	31.03.2014	30.06.2014	31.03.2014	30.06.2013	31.03.2014
		(Un-Audited)	(Audited)	(Un-Audited)	(Audited)	(Un-Audited)	(Audited)	(Un-Audited)	(Audited)
1	Income from operations								
	(a) Net Sales/income from operation (Net of excise duty)	4694.95	6478.85	3795.38	20908.58	4637.06	6186.01	3742.60	20478.08
	(b) Other operating income	216.02	196.85	205.29	618.15	196.90	129.22	180.62	511.05
	Total income from operations (net)	4910.97	6675.70	4000.67	21526.73	4833.96	6315.23	3923.22	20989.13
2	Expenses								
	(a) Cost of materials consumed	1226.96	2081.01	911.70	5226.85	969.48	1472.20	599.69	4050.05
	(b) Purchases of stock-in-trade	1272.97	2734.60	1395.66	9220.45	1702.20	3267.05	1813.81	10578.20
	(c) Changes in inventories of finished goods,work-in-progress and stock-in-trade	277.69	38.22	-96.26	-314.09	218.68	61.84	-65.21	-209.31
	(d) Employee benefits expense	432.46	471.76	488.06	1894.71	379.55	405.64	418.26	1618.77
	(e) Depreciation and amortisation expense	111.28	87.88	85.76	352.65	70.79	57.09	55.02	227.94
	(f) Other expenses	983.68	814.13	797.57	3234.57	847.98	728.47	725.48	2931.26
	Total expenses	4305.04	6227.60	3582.49	19615.14	4188.68	5992.29	3547.05	19196.91
3	Profit/(Loss) from operations before other income,finance costs and exceptional items (1-2)	605.93	448.10	418.18	1911.59	645.28	322.94	376.17	1792.22
4	Other income	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
5	Profit / (Loss) from ordinary activities before finance costs and exceptional items(3+ 4)	605.93	448.10	418.18	1911.59	645.28	322.94	376.17	1792.22
6	Finance costs	184.70	312.18	145.23	704.47	138.10	225.92	93.12	537.82
7	Profit / (Loss) from ordinary activities after finance costs but before exceptional items(5 - 6)	421.23	135.92	272.95	1207.12	507.18	97.02	283.05	1254.40
8	Exceptional items	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
9	Profit / (Loss) from ordinary activities before tax (7 + 8)	421.23	135.92	272.95	1207.12	507.18	97.02	283.05	1254.40
10	Tax expense	117.44	58.58	-35.09	188.67	122.57	39.14	-66.99	111.64
11	Net Profit / (Loss) from ordinary activities after tax (9 - 10)	303.79	77.34	308.04	1018.45	384.61	57.88	350.04	1142.76
12	Extraordinary items (net of tax expense)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
13	Net Profit / (Loss) for the period (11 - 12)	303.79	77.34	308.04	1018.45	384.61	57.88	350.04	1142.76
14	Share of profit / (loss) of associates*	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
15	Minority interest *	-19.05	7.67	-16.06	-46.96	0.00	0.00	0.00	0.00
16	Net Profit / (Loss) after taxes, minority interest and shares of profit/(loss) of associates ((13 - (14 +15)) *	322.84	69.67	324.10	1065.41	384.61	57.88	350.04	1142.76
17	Paid-up equity share capital of face value Rs.10/- each	1631.08	1631.08	1631.08	1631.08	1631.08	1631.08	1631.08	1631.08
18	Reserve excluding Revaluation Reserves as per balance sheet of previous a/c. year	----	----	----	8252.84	----	----	----	8281.66
19.i	a) Basic and diluted EPS before Extraordinary items(f.v.10/- each) and Prior period Adjustment.(Not Annualised)	1.98	0.43	1.99	6.53	2.36	0.35	2.15	7.00
19.ii	b) Basic and diluted EPS after Extraordinary items (f.v.10/- each) and Prior period Adjustment.(Not Annualised)	1.98	0.43	1.99	6.53	2.36	0.35	2.15	7.00
PART - II									
A PARTICULARS OF SHAREHOLDING									
1	Public Shareholding:								
	-Number of shares	10984449	10979649	10972268	10979649	10984449	10979649	10972268	10979649
	-Percentage of Shareholding	67.34	67.32	67.27	67.32	67.34	67.32	67.27	67.32
2	Promoters and Promoter group Shareholding:								
	a) Pledged/Encumbered								
	-Number of shares	NIL	NIL	NIL	NIL	NIL	NIL	NIL	NIL
	-Percentage of Shareholding (as a %of the total shareholding of promoter and promoter group)	NIL	NIL	NIL	NIL	NIL	NIL	NIL	NIL
	-Percentage of Shareholding (as a %of the total share capital of the Company)	NIL	NIL	NIL	NIL	NIL	NIL	NIL	NIL
	b) Non-encumbered								
	-Number of shares	5326351	5331151	5338532	5331151	5326351	5331151	5338532	5331151
	-Percentage of Shareholding (as a %of the total shareholding of promoter and promoter group)	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00
	-Percentage of Shareholding (as a %of the total share capital of the Company)	32.66	32.68	32.73	32.68	32.66	32.68	32.73	32.68
	Particulars	Quarter ended on 30.06.2014							
B INVESTOR COMPLAINTS									
	Pending at the beginning of the quarter	NIL							
	Received during the quarter	1							
	Disposed of during the quarter	1							
	Remaining unresolved at the end of the quarter	NIL							
NOTES:-									
<p>1. The above results were reviewed by the audit committee and approved by the Board of Directors at its meeting held on 14.08.2014.</p> <p>2. Consequent to the applicability of the Companies Act, 2013 (the Act) to Accounting periods commencing on or after April 1, 2014 the Company has computed the depreciation charge for the quarter with reference to the estimated useful lives of the Fixed Assets as prescribed in schedule II of the Act. Further, Rs.73,98,875/- the carrying value (net of residual value) of assets whose remaining useful life is Nil as on 1st April, 2014 has been recognised in the opening balance of retained earnings. Based on the past experience, residual value of computers is estimated @2.50% of the cost price instead of 5% of the cost price prescribed under schedule II to the Act.</p> <p>3. Previous year figures are regrouped/reclassified to confirm to the current year's presentation.</p> <p>4. Since the revenue from different segment is less than 10% of total revenue, segment wise results are not given.</p> <p>5. Statutory Auditors has carried out limited review for the quarterly result for quarter ended 30.06.2014.</p> <p>6. Consolidated results includes results of its two subsidiary Company.</p> <p>7. Company has opted to publish standalone Results for the year 2014-15</p>									
Place : Ahmedabad.						for LINCOLN PHARMACEUTICALS LIMITED			
Date : 14.08.2014						sd/- (Mahendra G. Patel) Managing Director			